The majority of BRCA1-deficient breast cancer cases are classified as triple-negative breast cancer based on the absence of expression of estrogen receptor (ER), progesterone receptor (PR), and HER29, and targeted therapy for this type of cancer is difficult. This evidence concerns the gene PGR and triple-negative breast carcinoma.